Edition:
United Kingdom

Calithera Biosciences Inc (CALA.OQ)

CALA.OQ on NASDAQ Stock Exchange Global Select Market

5.93USD
23 Apr 2018
Change (% chg)

$-0.17 (-2.87%)
Prev Close
$6.10
Open
$6.10
Day's High
$6.15
Day's Low
$5.93
Volume
51,080
Avg. Vol
111,070
52-wk High
$20.00
52-wk Low
$5.38

Chart for

About

Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic... (more)

Overall

Beta: 2.60
Market Cap(Mil.): $218.65
Shares Outstanding(Mil.): 35.84
Dividend: --
Yield (%): --

Financials

  CALA.OQ Industry Sector
P/E (TTM): -- 185.04 32.78
EPS (TTM): -0.85 -- --
ROI: -27.31 -0.74 13.21
ROE: -27.80 -2.80 15.01

BRIEF-Calithera Biosciences Announces FDA Fast Track Designation Granted To CB-839 In Combination With Cabozantinib For Treatment Of Patients With Advanced Renal Cell Carcinoma

* CALITHERA BIOSCIENCES ANNOUNCES FDA FAST TRACK DESIGNATION GRANTED TO CB-839 IN COMBINATION WITH CABOZANTINIB FOR TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA Source text for Eikon: Further company coverage:

18 Apr 2018

BRIEF-Calithera Biosciences Qtrly Net Loss From Operations $11.0 Mln

* CALITHERA BIOSCIENCES REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS AND RECENT HIGHLIGHTS

08 Mar 2018

BRIEF-Calithera Biosciences Says Plans To Initiate A Global, Randomized Phase 2 Trial Of CB-839 In Combination With Cabozantinib In Q2 Of 2018

* CALITHERA BIOSCIENCES INC - PLAN TO INITIATE A GLOBAL, RANDOMIZED PHASE 2 TRIAL OF CB-839 IN COMBINATION WITH CABOZANTINIB IN Q2 OF 2018 Source text for Eikon: Further company coverage:

05 Feb 2018

BRIEF-Calithera Biosciences expands clinical collaboration with Bristol-Myers Squibb

* Initial results from Phase 2 study of CB-839 in combination with opdivo® (nivolumab) to be presented at the Society for Immunotherapy of Cancer Meeting

07 Nov 2017

BRIEF-Calithera Biosciences Q3 operating loss per share $0.17

* Calithera biosciences reports third quarter 2017 financial results and recent highlights

02 Nov 2017

Competitors

  Price Chg
Agios Pharmaceuticals Inc (AGIO.OQ) $85.66 -0.79
AstraZeneca plc (AZN.L) 5,015.00 +39.00
Bayer AG (BAYGn.DE) €98.79 -0.21
Bayer AG (BAYE.F) -- --
Celgene Corporation (CELG.OQ) $89.49 +0.54
Eli Lilly And Co (LLY.N) $80.20 +1.14
GlaxoSmithKline plc (GSK.L) 1,445.00 +15.00
Merck KGaA (MRCG.DE) €82.28 +0.26
Novartis AG (NOVN.S) CHF76.04 -0.04
Pfizer Inc. (PFE.N) $36.80 +0.17

Earnings vs. Estimates